Jo is Senior Vice President CMC (Chemistry Manufacturing & Controls) for NeRRe Therapeutics, a clinical stage biotech company located at the Stevenage Biosciences Catalyst.

Jo is a Pharmacist and has spent her entire career working in the pharmaceutical industry with a focus on pharmaceutical development, product quality and the introduction of new manufacturing technologies. Prior to Jo’s NeRRe Therapeutics role, she held the same role for KaNDy Therapeutics prior to its acquisition by Bayer in 2020.

Previously, Jo spent over 30 years at GlaxoSmithKline where her career spanned many leadership roles in CMC product development, most recently as Vice President of Technology & Strategy, Product Development & Supply. Jo led the technology team at the Medicines Manufacturing Industry Partnership (MMIP) 2017-2018 where she was influential in aligning Pharma and UK Government on future areas for investment as part of the Life Sciences Industrial Strategy. She continues to be involved with medicines manufacturing in the UK contributing to advisory groups. Jo is a Fellow of the Royal Pharmaceutical Society, an Eminent Fellow of the Academy of Pharmaceutical Sciences, UK and has been an Advisor to the APS Board for several years.

Jason is Team Director, Drug Product Development, Oral and Inhaled, GlaxoSmithKline.

Jason completed his undergraduate and post graduate education in Pharmacy at Kings College London. In 1997 he joined the SmithKline Beecham clinical manufacturing group where he built experience in the manufacture and release of oral and intravenous dose forms and since then has led several multidisciplinary teams in the development, registration and launch of IV and OSD products across the GSK portfolio. This has included assignments in medicine and process delivery, cell and gene therapy and more recently in process engineering and analytics focussed on platform modernisation and alignment.

Linda has more than 40 years’ experience in the pharmaceutical industry, having worked for companies such as Glaxo, Marion Merrell Dow, Celltech, Eli Lilly, Schwarz Pharma AG and UCB Biosciences. Her experience covers pharmaceutical development, preclinical development, clinical trial supplies, quality assurance and project leadership. Since 2016 Linda has been an independent consultant with a focus on pharmaceutical development and development strategy.

Linda is a Vice President of FIP (International Pharmaceutical Federation), a member of the Assembly of Royal Pharmaceutical Society (RPS) and the immediate past Chairman of the Academy of Pharmaceutical Sciences. She is also visiting Professor at Sunderland University and is eligible to be a Qualified Person. Linda is a Fellow of both the Royal Pharmaceutical Society and FIP.

David is Pro-Vice-Chancellor (Education and Students) and Professor of Biomaterials Science at Queen’s University Belfast.

As an internationally renowned pharmaceutical/biomedical engineer my research seeks to provide engineering solutions to medical and pharmaceutical problems. These include innovations in the design of drug containing implants and medical devices to that reduce the morbidity and mortality associated with medical device related infection. Commercialisation of this research has occurred and is ongoing. Within the pharmaceutical domain, I have developed novel implants for the treatment of local diseases and, additionally, engineering technologies to develop new dosage forms, including strategies in which drugs of low solubility (negating their clinical utility) may be developed for clinical usage.

Trevor is Chairman of the Drug Discovery Company, e-Therapeutics and a member of the Boards of Directors of Techimmune LLC and EDX Medical plc. He was a Director of Allergan Inc. (USA), R&D Director of The Wellcome Foundation and Director General of The ABPI.

He holds honorary degrees and Gold Medals from 8 universities; is a founder member of Medicines for Malaria Venture (MMV);was a member of The UK Government Regulatory Agency, The Medicines Commission; advisor to the Cabinet Office on the Human Genome project; Chair of the UK Government Advisory Group on Genetics Research; member of the Wales Government Bevan Commission on health; the EU Commission IMI Scientific Advisory Board…and advised the Government of the Netherlands TiPharma on Life Science.

Jayne is currently Professor and Head of Pharmacy and Optometry at the University of Manchester University. Prior to this she was Professor and Head of the Pharmaceutical Biophysics Group, Institute of Pharmaceutical Science, King’s College London and Chief Scientist at the Royal Pharmaceutical Society.

Jayne is a pharmacist who. in addition to working in academia, has spent time working in community, hospital and industrial pharmacy. Her research is focuses on improving the delivery of drugs and genetic material, with a special interest determining detailed the molecular architecture of the delivery systems using neutron scattering techniques. Jayne also uses neutron reflectometry to understand the interaction of drugs and genetic material with biomembranes.

Dr Mark McAllister is a Senior Director and Head of Global Biopharmaceutics, part of the Drug Product Design group at Pfizer in Sandwich, Kent. He is a Pharmacy graduate from Queen’s University Belfast and has a pharmaceutics PhD from Aston University. Mark has over 25 years industrial development experience and has specialised in oral delivery systems and biopharmaceutics. He is a former chair of the Academy of Pharmaceutical Sciences and is currently a visiting senior lecturer at King’s College London.

Mark co-led the IMI ‘OrBiTo’ biopharmaceutics project, an academic/industrial collaboration, focused on the development of the next generation of models to predict oral absorption and he currently participates in a number of pre-competitive research programmes including COLOTAN, AGePOP and InPharma Marie Skłodowska-Curie innovative training networks. Mark is a fellow of the Royal Pharmaceutical Society and the Academy of Pharmaceutical Sciences.

John is a chemist with over 40 years’ experience in Pharmaceutical Development gained with a number of major pharmaceutical companies.

He obtained his BSc from Bristol University and his PhD (part-time) from University of Nottingham School of Pharmacy. Until November 2010 he was a Vice President in GlaxoSmithKline and ran various multi-national departments involved with analytical chemistry, Product Line Extension development, physical properties and developability and early stage CMC support. He has a good knowledge of Quality by Design, Change Control and Technology Transfer. He is currently CEO of John Wahlich Associates Ltd a consulting company specialising in the pharmaceutical sciences.

John is currently consulting for a number of companies on early stage product development. He is an Advisory Board member of the UK Academy of Pharmaceutical Sciences (APS), has co-hosted successful workshops on drug developability and has co-organised a number of APS International Pharm Sci conferences (the UK’s premier Pharm Sci event).